期刊文献+

原发性肝细胞肝癌的TACE联合外科治疗及单纯外科手术治疗对照研究 被引量:11

Control Study of Surgery Combined with TACE and Simple Surgical Treatment on HCC
暂未订购
导出
摘要 对比单纯外科治疗以及外科手术联合TACE治疗原发性肝癌的疗效以及生存时间。回顾性分析我院2006年至2009年的260例原发性肝癌的治疗情况,分为单纯外科组(对照组)以及TACE联合外科手术组进行对照研究,比较术后3月的疾病控制率;并比较其1,2,3年生存率,以kaplan—Meier生存曲线进行生存分析。结果3个月时疾病控制率单纯手术组为75.70%,TACE联合手术组为85.62%,P=0.043有统计学差异。单纯手术组第1、2、3年生存率为55.14%,15.89%,9.35%;TACE联合手术组为66.01%,27.45%,18.95%,第1年生存率两者没有统计学差异,P=0.076;第2、3年生存率联合组明显高于单纯手术组,P=0.029,P=0.033。因此,TACE联合外科手术治疗原发性肝细胞肝癌的远期疗效比单纯手术有明显优势。 To compare effects and life cycle of simple surgical treatment and surgery combined with trans--catheter arterial chemo--embolization (TACE) on patients with advanced un--resectable hepatocellular carcinoma (HCC). Clinical data of 260 consecutive patients who underwent hepatectomy for HCC in our hospital from 2006 to 2009 were analyzed retrospec- tively. According to the different treatment modalities, these patients have been divided into simple surgical group ( control group) and group of surgery combined with TACE (combined group) to proceed controlled studies and to compare the Disease Control Rate ( DCR) three months after patients'operation, to compare 3 year survival rates and analyzed using Kaplan--Meier survival curves. For control group and combined group, the 3--month DCR were 75.70 % and 85.62 %respec- tively (P=0. 043) there was a statistically difference. For control group, 1, 2 and 3 year survival rates were 55.14%, 15.89%, 9.35% respectively; for combined group, the rates were 66.01%, 27.45%, 18.95% accordingly. There was no significant differences for 1 year survival rates (P= 0. 076), but 2 and 3 year survival rates of combined group were ap- parently higher than control group (P = 0. 029, P: 0. 033). The long--term effect of surgery combined with TACE on patients with advanced un--resectable HCC has a distinct advantage over those of simple surgical treatment.
机构地区 湖南省人民医院
出处 《医学与哲学(B)》 2012年第11期16-18,共3页 Medicine & Philosophy(B)
关键词 原发性肝癌 外科手术切除 肝动脉栓塞化疗 carcinoma, surgical excision, trans-- catheter arterial chemo-- embolization (TACE)
  • 相关文献

参考文献5

二级参考文献37

  • 1姜宝法,刘春晓,崔永春,徐涛,徐敏,王家林,杜君.EORTCQLQ-C30的信度、效度研究[J].中国临床心理学杂志,2005,13(1):31-32. 被引量:151
  • 2丛文铭,吴孟超.小肝细胞癌的临床病理特点:附93例分析[J].中华肿瘤杂志,1993,15(5):372-374. 被引量:35
  • 3孟琼,万崇华,罗家洪.癌症患者生命质量测定量表EORT CQLQ-C30的应用[J].中国行为医学科学,2005,14(3):273-274. 被引量:173
  • 4I.lovet J M, Di Bisceglie A M, Bruix J, el al. Design and endpoints of clinical trials in hepatoccllular carcinoma[J]. J Natl Canccr lnst, 2008, 100(10):698- 711.
  • 5Bruix J, Llovet J M. Prognostic assessment and ewtluation of tim benefits of treatment[J]. J Clin C-asroenlerol, 2002,35(5 SiJppl 2) :$138-142.
  • 6Foulkes W D, Reis - Filho J S, Narod S A. Tumor size and surviv alinbreast cancer a reappraisal[J]. Nat RevClinOncol ,2010,7: 348-353.
  • 7Budhu A, Forgues M, Ye Q H, et al. Prediction of venous metas tases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenviron ment[J]. Cancer Cell, 2006, 10(2):99-111.
  • 8HoshidaY, Villanueva A, Kobayashi M, et al. Gcne expression in fixed tissues and outcome in hepatoeellular carcinoma[J].N Engl J Med,2008,359(19) : 1995-2004.
  • 9Ji J, Shi J, Budhu A, et aI. MicroRNA expression, survival, and response to imerferon in liver cancer[J]. N Engl J Meal, 2009,361 (15):1437-1447.
  • 10Chen H, Xu L, QiQ, et al. A haplotypcvariationaffeclinglhl mi tochondrial transportation of hMYH protein could be a risk factur for colorectal cancer in Chinese[J]. BMC Cancer,2008,8 : 269.

共引文献92

同被引文献118

引证文献11

二级引证文献80

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部